Overexpression of apolipoprotein CIII increases and CETP reverses diet-induced obesity in transgenic mice

International Journal of Obesity

Volumn 31, Issue 10, 2007, Pages 1586-1595

  Salerno, A G ^a   Silva, T R ^a   Amaral, M E C ^a   Alberici, L C ^a   Bonfleur, M L ^a   Patricio P R ^a   Francesconi, E P M S ^a   Grassi Kassisse, D M ^a   Vercesi, A E ^a   Boschero, A C ^a   Oliveira, H C F ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Apolipoprotein CIII; CETP; Diet induced obesity; Hypertriglyceridemia; Leptin; Mitochondrial respiration

Indexed keywords

APOLIPOPROTEIN C3; CHOLESTEROL ESTER TRANSFER PROTEIN; GLUCOSE; INSULIN; LEPTIN;

ADIPOCYTE; ADIPOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CARCASS; CELL SIZE; CONTROLLED STUDY; DIET RESTRICTION; DISEASE EXACERBATION; ENERGY EXPENDITURE; FEMALE; GENE OVEREXPRESSION; GENOTYPE; GLUCOSE BLOOD LEVEL; HORMONE BLOOD LEVEL; INSULIN BLOOD LEVEL; INTRAABDOMINAL FAT; LIPID DIET; MALE; MITOCHONDRIAL ENERGY TRANSFER; MITOCHONDRIAL RESPIRATION; MOUSE; NONHUMAN; OBESITY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; SUBCUTANEOUS FAT; TRANSGENIC MOUSE; WEANING;

ANIMALS; APOLIPOPROTEIN C-III; BODY COMPOSITION; BODY WEIGHT; CHOLESTEROL ESTER TRANSFER PROTEINS; FASTING; HYPERTRIGLYCERIDEMIA; LEPTIN; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; OBESITY;

MUS; MUS MUSCULUS;

EID: 34748831650     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/sj.ijo.0803646     Document Type: Article

References (54)

1. Mancini M, Steiner G, Betteridge DJ, Pometta D. Acquired (secondary) forms of hypertriglyceridemia. Am J Cardiol 1991; 68: A17-A21.
2. Assmann G, Brewer Jr HB. Genetic (primary) forms of hypertriglyceridemia. Am J Cardiol 1991; 68: A13-A16.
3. Jong MC, Hofker MH, Havekes LM. Role of apoCs in lipoprotein metabolism: functional differences between apoC1, apoC2, and apoC3. Arterioscle Thromb Vas Biol 1999; 19: 472-484.
4. Jong MC, Rensen PC, Dahlmans VE, Van Der Boom H, Van Berkel TJ, Havekes LM. Apolipoprotein C-III deficiency accelerates triglyceride hydrolysis by lipoprotein lipase in wild-type and apoE knockout mice. J Lipid Res 2001; 42: 1578-1585.
5. Kashyap ML, Srivasta LS, Hynd BA, Gartside PS, Perisutti G. Quantitation of human apolipoprotein C-III and its subspecies by radioimmunoassay and analytical isoelectric focusing: abnormal plasma triglyceride-rich lipoprotein apolipoprotein C-III subspecie concentrations in hypertriglyceridemia. J Lipid Res 1981; 22: 800-810.
6. Fredenrich A, Giroux LM, Tremblay M, Krimbou L, Davignon J, Cohn JS. Plasma lipoprotein distribution of apoC-III in normolipidemic and hypertriglyceridemic subjects: comparison of the apoCIII to apoE ratio in different lipoprotein fractions. J Lipid Res 1997; 38: 1421-1432.
7. Ito Y, Azrolan N, O'connell A, Walsh A, Breslow JL. Hypertriglyceridemia as a result of human apolipoprotein C-III gene expression in transgenic mice. Science 1990; 249: 790-793.
8. Aalto-Setala K, Fisher EA, Chen X, Chajekshaul T, Hayek T, Zechner R et al. Mechanism of hypertriglyceridemia in human apolipoprotein (apo) C-III transgenic mice: diminished very low density lipoprotein fractional catabolic rate associated with increased apoCIII and reduced apoE on the particles. J Clin Invest 1992; 90: 1889-1900.
9. De Silva HV, Lauer SJ, Wang J, Simonett WS, Weisgraber KH, Mahley RW et al. Overexpression of human apolipoprotein C-III in transgenic mice results in accumulation of apolipoprotein B48 remnant that is corrected by excess apolipoprotein E. J Biol Chem 1994; 269: 2324-2335.
10. Forte TM, Nichols AV, Krauss RM, Norum RA. Familial apolipoprotein AI and apolipoprotein CIII deficiency. Subclass distribution, composition, and morphology of lipoproteins in a disorder associated with premature atherosclerosis. J Clin Invest 1984; 74: 1601-1613.
11. Von Eckardstein A, Holz H, Sandkamp M, Weng W, Funke H, Assmann G. Apolipoprotein C-III(Lys58- - - -Glu). Identification of an apolipoprotein C-III variant in a family with hyperalphalipoproteinemia. J Clin Invest 1991; 87: 1724-1731.
12. Maeda N, Li H, Lee D, Oliver P, Quarfordt SH, Osada J. Targeted disruption of the apolipoprotein C-III gene in mice results in hypotriglyceridemia and protection from postprandial hypertriglyceridemia. J Biol Chem 1994; 269: 10-16.
13. Ebara T, Ramakrishnan R, Steiner G, Shachter NS. Chylomicronemia due to apolipoprotein C-III overexpression in apolipoprotein E-null mice: apolipoprotein C-III-induced hypertriglyceridemia is not mediated by effects on apoE. J Clin Invest 1997; 99: 2672-2681.
14. Kowal RC, Herz J, Weisgraber KH, Mahley RW, Brown MS, Goldstein JL. Opposing effects of apolipoprotein E and C on lipoprotein binding to low density lipoprotein receptor-related protein. J Biol Chem 1990; 265: 10771-10779.
15. Sehayek E, Eisenberg S. Mechanisms of inhibition by apolipoprotein C of apolipoprotein E-dependent cellular metabolism of human triglyceride-rich lipoproteins through the low-density lipoprotein receptor pathway. J Biol Chem 1991; 266: 18259-18267.
16. Aalto-Setala K, Weinstock PH, Bisgaier CL, Wu L, Smith JD, Breslow JL. Further characterization of the metabolic properties of triglyceride-rich lipoproteins from human and mouse apoC-III transgenic mice. J Lipid Res 1996; 37: 1802-1811.
17. Tall AR. Plasma cholesteryl ester transfer protein. J Lipid Res 1993; 34: 1255-1274.
18. Ha YC, Barter PJ. Differences in plasma cholesteryl ester transfer activity in sixteen vertebrate species. Comp Biochem Physiol B 1982; 71: 265-269.
19. Jiang X, Moulin P, Quinet E, Goldberg IJ, Yacoub LK, Agellon LB et al. Mammalian adipose tissue and muscle are major sources of lipid transfer protein mRNA. J Biol Chem 1991; 266: 4631-4639.
20. Agellon LB, Walsh A, Hayek T, Moulin P, Jiang XC, Shelanski SA et al. Reduced high density lipoprotein cholesterol in human cholesteryl ester transfer protein transgenic mice. J Biol Chem 1991; 266: 10796-10801.
21. Jiang XC, Agellon LB, Walsh A, Breslow JL, Tall AR. Dietary cholesterol increases transcription of the human cholesteryl ester transfer protein gene in transgenic mice. Dependence on natural flanking sequences. J Clin Invest 1992; 90: 1290-1295.
22. Marotti KR, Castle CK, Boyle TP, Lin AH, Murray RW, Melchior GW. Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein. Nature 1993; 364: 73-75.
23. Plump AS, Masucci-Magoulas L, Bruce C, Bisgaier CL, Breslow JL, Tall AR. Increased atherosclerosis in ApoE and LDL receptor gene knock-out mice as a result of human cholesteryl ester transfer protein transgene expression. Arterioscler Thromb Vasc Biol 1999; 19: 1105-1110.
24. Harada LM, Amigo L, Cazita PM, Salerno AG, Rigotti AA, Quintão EC et al. CETP expression enhances liver HDL-cholesteryl ester uptake but does not alter VLDL and biliary lipid secretion. Atherosclerosis 2007; 191: 313-318.
25. Vassiliou G, Mcpherson R. Role of cholesteryl ester transfer protein in selective uptake of high-density lipoprotein cholesteryl esters by adipocytes. J Lipid Res 2004; 45: 1683-1693.
26. Gauthier A, Lau P, Zha X, Milne R, Mcpherson R. Cholesteryl ester transfer protein directly mediates selective uptake of high-density lipoprotein cholesteryl esters by the liver. Arterioscler Thromb Vasc Biol 2005; 25: 2177-2184.
27. Hayek T, Masucci-Magoulas L, Jiang X, Walsh A, Rubin E, Breslow JL et al. Decreased early atherosclerotic lesions in hypertriglyceridemic mice expressing cholesteryl ester transfer protein transgene. J Clin Invest 1995; 96: 2071-2074.
28. Cazita PM, Berti JA, Aoki C, Gidlund M, Harada LM, Nunes VS et al. Cholesteryl ester transfer protein expression attenuates atherosclerosis in ovariectomized mice. J Lipid Res 2003; 44: 33-40.
29. Casquero AC, Berti JA, Salerno AG, Bighetti EJ, Cazita PM, Ketelhth DF et al. Atherosclerosis is enhanced by testosterone deficiency and attenuated by CETP expression in transgenic mice. J Lipid Res 2006; 47: 1526-1534.
30. Clark RW. Raising high-density lipoprotein with cholesteryl ester transfer protein inhibitors. Curr Opin Pharmacol 2006; 6: 162-168.
31. Pearson H. When good cholesterol turns bad. Nature 2006; 444: 794-795.
32. Tall AR, Yvan-Charvet L, Wang N. The failure of torcetrapib: was it the molecule or the mechanism? Arterioscler Thromb Vasc Biol 2007; 27: 257-260.
33. Zhou H, Li Z, Hojjati MR, Jang D, Beyer TP, Cao G et al. Adipose tissue specific CETP expression in mice: impact on lipoprotein metabolism. J Lipid Res 2006; 47: 2011-2019.
34. Alberici LC, Oliveira HCF, Patrício PR, Kowaltowski AJ, Vercesi AE. Hyperlipidemic mice present enhanced catabolism and higher mitochondrial ATP-sensitive K+ channel activity. Gastroenterology 2006; 131: 1228-1234.
35. Duivenvoorden I, Teusink B, Rensen PC, Romijn JA, Havekes LM, Voshol PJ. Apolipoprotein C3 deficiency results in diet-induced obesity and aggravated insulin resistance in mice. Diabetes 2005; 54: 664-671.
36. Jong MC, Voshol PJ, Muurling M, Dahlmans VE, Romijn JA, Pijl H et al. Protection from obesity and insulin resistance in mice overexpressing human apolipoprotein C1. Diabetes 2001; 50: 2779-2785.
37. Walsh A, Azrolan N, Wang K, Marcigliano A, O'connell A, Breslow JL. Intestinal expression of the human apoA-I gene in transgenic mice is controlled by a DNA region 3′ to the gene in the promoter of the adjacent convergently transcribed apoC-III gene. J Lipid Res 1993; 34: 617-623.
38. Berti JA, Amaral ME, Boschero AC, Nunes VS, Harada LM, Castilho LN et al. Thyroid hormone increases plasma cholesteryl ester transfer protein activity and plasma high-density lipoprotein removal rate in transgenic mice. Metabolism 2001; 50: 530-536.
39. Scott AM, Atwater I, Rojas E. A method for the simultaneous measurement of insulin release and B cell membrane potential in single mouse islets of Langerhans. Diabetologia 1981; 21: 470-475.
40. Rodbell M. Metabolism of isolated fat cells. Effects of hormones on glucose metabolism and lipolysis. J Biol Chem 1964; 239: 375-380.
41. Kaplan RS, Pedersen PL. Characterization of phosphate efflux pathways in rat liver mitochondria. Biochem J 1983; 212: 279-288.
42. Boschero AC, Szpak-Glasman M, Carneiro EM, Bordin S, Paul I, Rojas E et al. Oxotremorine-m potentiation of glucose-induced insulin release from rat islets involves M3 muscarinic receptors. Am J Physiol 1995; 268: E336-E342.
43. Van Harmelen V, Dicker A, Rydén M, Hauner H, Lonnqvist F, Naslund E et al. Increased lipolysis and decreased leptin production by human omental as compared with subcutaneos preadipocytes. Diabetes 2002; 51: 2029-2036.
44. Amaral ME, Oliveira HCF, Carneiro EM, Delghingaro-Augusto V, Vieira EC, Berti JA et al. Plasma glucose regulation and insulin secretion in hypertriglyceridemic mice. Horm Metab Res 2002; 34: 21-26.
45. Reaven GM, Mondon CE, Chen YD, Breslow JL. Hypertriglyceridemic mice transgenic for the human apolipoprotein C-III gene are neither insulin resistant nor hyperinsulinemic. J Lipid Res 1994; 35: 820-824.
46. Biddinger SB, Kahn CR. From mice to men: insights into the insulin resistance syndromes. Annu Rev Physiol 2006; 68: 123-158.
47. Yin W, Liao D, Kusunoki M, Xi S, Tsutsumi K, Wang Z et al. NO-1886 decreases ectopic lipid deposition and protects pancreatic beta cells in diet-induced diabetic swine. J Endocrinol 2004; 180: 399-408.
48. Araujo EP, De Souza CT, Gasparetti AL, Ueno M, Boschero AC, Saad MJ et al. Short-term in vivo inhibition of insulin receptor substrate-1 expression leads to insulin resistance, hyperinsulinemia, and increased adiposity. Endocrinology 2005; 146: 1428-1437.
49. Conde-Knape K, Okada K, Ramakrishnan R, Shachter NS. Overexpression of apoC-III produces lesser hypertriglyceridemia in apoB-48-only gene-targeted mice than in apoB-100-only mice. J Lipid Res 2004; 45: 2235-2244.
50. Le Lay S, Krief S, Farnier C, Lefrere I, Le Liepvre X, Bazin R et al. Cholesterol, a cell size-dependent signal that regulates glucose metabolism and gene expression in adipocytes. J Biol Chem 2001; 276: 16904-16910.
51. Asayama K, Hayashibe H, Dobashi K, Uchida N, Nakane T, Kodera K et al. Increased serum cholesteryl ester transfer protein in obese children. Obes Res 2002; 10: 439-446.
52. Arai T, Yamashita S, Hirano K, Sakai N, Kotani K, Fujioka S et al. Increased plasma cholesteryl ester transfer protein in obese subjects. A possible mechanism for the reduction of serum HDL cholesterol levels in obesity. Arterioscler Thromb 1994; 14: 1129-1136.
53. Teran-Garcia M, Despres JP, Tremblay A, Bouchard C. Effects of cholesterol ester transfer protein (CETP) gene on adiposity in response to long-term overfeeding. Atherosclerosis 2006 [ahead of print, DOI: 10.1016/j.atherosclerosis.2006.12.005].
54. Boekholdt SM, Thompson JF. Natural genetic variation as a tool in understanding the role of CETP in lipid levels and disease. J Lipid Res 2003; 44: 1080-1093.